Search Results
Your search for ,ArM matches 4703 pages
Showing 2351 - 2400Novel Therapies for Small Cell Lung Cancer and Neuroendocrine Tumors
Here is a glimpse at updated clinical trial data on newer therapies under study for the small cell lung cancer (SCLC) and advanced extrapancreatic neuroendocrine tumors. IMpower133 and ALTER: Novel Therapies for SCLC The treatment of small cell lung cancer has seen little progress in recent years, ...
Pivotal Phase III Study Evaluates Investigational TKI in Fourth-Line Setting for Advanced GIST
In a late-breaking, oral presentation at the ESMO Congress 2019, Margaret von Mehren, MD, presented results from INVICTUS, a pivotal phase III clinical trial of ripretinib in patients with advanced gastrointestinal stromal tumor (GIST).1 Ripretinib is an investigational tyrosine kinase inhibitor...
Targeted Treatment Advances in Cholangiocarcinoma
For one of the rarest and most aggressive of tumors—cholangiocarcinoma—two novel molecularly targeted agents yielded encouraging outcomes in advanced disease in studies reported at the European Society for Medical Oncology (ESMO) Congress 2019. In the phase III ClarIDHy trial, the risk of disease...
Phase III PROfound Study Evaluates Olaparib in Setting of Metastatic, Castration-Resistant Prostate Cancer
Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib delayed disease progression and appears to improve survival, compared with newer hormonal agents in men with pretreated metastatic castration-resistant prostate cancer and homologous recombinant repair (HRR) genetic...
Expert Point of View: Nicoletta Colombo, MD
The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...
Immunotherapy Shows Strong Benefit in Two Gynecologic Cancers
In studies reported at the ESMO Congress 2019, immunotherapy yielded encouraging outcomes in two gynecologic cancer populations in need of new treatments, including patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer. ...
CheckMate 227: Nivolumab Plus Ipilimumab Presents Another Option in First-Line Treatment of Advanced Non–Small Cell Lung Cancer
The combination of nivolumab and ipilimumab improved overall survival compared with chemotherapy as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) expression of at least 1%, according to the results of CheckMate 227....
Osimertinib Improves Overall Survival vs Gefitinib, Erlotinib in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: FLAURA Phase III Trial
The third-generation tyrosine kinase inhibitor osimertinib extended overall survival compared with the older tyrosine kinase inhibitors gefitinib and erlotinib in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to late-breaking final overall survival results of the ...
Expert Point of View: Nicoletta Colombo, MD
The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...
Checkpoint Inhibitors Benefit Women With Advanced Stages of Cervical, Endometrial Cancers
Immunotherapy studies reported at the ESMO Congress 2019 yielded encouraging outcomes in patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer. The combination of nivolumab and ipilimumab, with two different dosing...
Phase III Trials Suggest Paradigm Shift With PARP Inhibitors in Ovarian Cancer
At the ESMO Congress 2019, ovarian cancer was a topic of heightened interest, particularly due to findings reported in several important phase III studies of PARP inhibitors in front-line maintenance therapy for patients with newly diagnosed advanced disease—and not just those with BRCA mutations....
Neoadjuvant Immunotherapy Plus Chemotherapy Active in Women With Early Triple-Negative Breast Cancer
Immunotherapy has changed the treatment paradigms for melanoma, lung cancer, bladder cancer, and renal cancer. Now, checkpoint inhibitor therapy is making inroads in triple-negative breast cancer—one of the most difficult-to-treat aggressive types of breast cancer. Late-breaking results of the...
MONALEESA-3, MONARCH 2: CDK4/6 Inhibitors Plus Fulvestrant Benefit Survival in Advanced Breast Cancer
CDK4/6 inhibitors improve overall survival in advanced breast cancer, according to results of two important phase III trials reported at the ESMO Congress 2019. Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles Women’s Cancer Research Program, presented the findings from the...
Prognostic Biomarkers in Triple-Negative Breast Cancer Treated With Adjuvant Doxorubicin/Cyclophosphamide
As reported in the Journal of Clinical Oncology by Priyanka Sharma, MD, and colleagues, biomarker analysis among women with triple-negative breast cancer treated with adjuvant doxorubicin/cyclophosphamide in the SWOG 9313c trial has confirmed a 44-gene DNA damage immune response signature and...
Expert Point of View: Ana Oaknin, MD, PhD
Ana Oaknin, MD, PhD, Head of the Gynecologic Cancer Program at Vall d’Hebron Institute of Oncology, Barcelona, discussed the PRIMA/ENGOT-OV26/GOG-3012 trial along with the results of the phase III PAOLA-1/ENGOT-ov25 trial of olaparib plus bevacizumab maintenance. According to Dr. Oaknin, the...
Third-Line Cabazitaxel Improves Outcomes in Patients With Metastatic Prostate Cancer
Third-line treatment with cabazitaxel extended progression-free survival and overall survival in men with metastatic castration-resistant prostate cancer in the CARD trial. These results provide the first evidence from a randomized phase III trial for a survival benefit with third-line therapy, and ...
Remembering Craig Alguire
It is with great sadness that we report Craig Alguire, MD, 42, died on October 11, 2019, at his home in Grand Rapids, Michigan. Diagnosed with grade 4 glioblastoma multiforme in 2015, Dr. Alguire chronicled the effects the cancer was having on his life in his Patient’s Corner column, published in...
Expert Point of View: Mansoor R. Mirza, MD
The time has come to offer all patients a PARP [poly (ADP-ribose) polymerase] inhibitor,” said Mansoor R. Mirza, MD, Chief Oncologist at Copenhagen University Hospital and the invited discussant of the VELIA trial at the ESMO Presidential Symposium. He noted, however, that he wasn’t sure veliparib...
Veliparib Plus Chemotherapy Meets Primary Endpoint in Advanced Ovarian Cancer
As first-line treatment for women with advanced ovarian cancer, the addition of veliparib during induction followed by veliparib maintenance therapy significantly reduced the risk of disease progression or death in the phase III VELIA/GOG-3005 trial reported at the European Society for Medical...
Immunotherapy Combinations Redefine Outcomes for Patients With Advanced Renal Cell Carcinoma
The treatment landscape for patients with advanced renal cell carcinoma has changed drastically over the past several years with the introduction of many new therapeutic options for patients. The revolution began with the U.S. Food and Drug Administration (FDA) approval of nivolumab and ipilimumab...
Abemaciclib Benefits Patients With HER2-Positive Breast Cancer in monarcHER Trial
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are associated with a robust benefit in patients with hormone receptor–positive, HER2-negative breast cancer, but now the monarcHER trial has confirmed their benefit in the HER2-positive population. The new findings were reported at the...
ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory FLT3-Mutated AML
As reported in The New England Journal of Medicine by Perl et al, the phase III ADMIRAL trial showed improved overall survival with the oral FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib vs salvage chemotherapy in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia...
Expert Point of View: Ana Oaknin, MD, PhD
“The main goal in ovarian cancer is to avoid relapse after first-line therapy because otherwise, the probability of cure is quite low,” said European Society for Medical Oncology (ESMO) discussant of the PAOLA-1 trial, Ana Oaknin, MD, PhD, of the Vall d’Hebron Institute of Oncology, Barcelona....
PAOLA-1 Trial: Front-Line Olaparib/Bevacizumab Maintenance Benefits Women With Advanced Ovarian Cancer
In women with newly diagnosed ovarian cancer, front-line maintenance therapy with olaparib plus bevacizumab reduced the risk of disease progression by 41% overall and by 69% in the subset of patients with BRCA-mutated disease, vs bevacizumab and placebo, in the phase III PAOLA-1/ENGOT-ov25 trial...
Expert Point of View: Thomas Powles, MD, PhD
In metastatic urothelial carcinoma, the bar has been set low, with a median survival of 1 year in cisplatin-eligible patients and 6 to 8 months when platinum-based therapy fails to elicit a response in patients, explained formal study discussant Thomas Powles, MD, PhD, Director, Bart’s Cancer...
IMvigor130 Trial: Atezolizumab Plus Chemotherapy for Metastatic Urothelial Cancer
Treatment with atezolizumab plus chemotherapy extended progression-free survival by 1.9 months vs chemotherapy alone in patients with metastatic urothelial cancer, according to the early results of the IMvigor130 trial, which were presented at the European Society for Medical Oncology (ESMO)...
Continuous Therapy for Multiple Myeloma Offers Survival Advantage, but Questions Remain
The number of approved agents in multiple myeloma has skyrocketed in recent years, leading to significant improvements in survival, but questions remain regarding the optimal duration of treatment. Although traditionally limited to a fixed number of cycles due to accumulating toxicity, novel agents ...
Targeted Therapy Moves Into Metastatic Castration-Resistant Prostate Cancer With Strong Showing by Olaparib and Rucaparib
Treatment with olaparib delayed disease progression, and early survival data suggest a positive trend in favor of olaparib compared with newer hormonal agents in men with pretreated metastatic castration-resistant prostate cancer and homologous recombinant repair genetic alterations—specifically...
Omitting Radiation From Treatment for Early-Stage Hodgkin Lymphoma Increases Risk of Recurrence
Two presentations at the American Society for Radiation Oncology (ASTRO) Annual Meeting offered more evidence that omitting radiation therapy leads to higher rates of recurrence for patients with early-stage Hodgkin lymphoma.1,2 Both studies involve work by the German Hodgkin Study Group among...
FDA Approves Niraparib for Patients With Homologous Recombination Deficiency–Positive Advanced Ovarian Cancer
On October 23, the U.S. Food and Drug Administration (FDA) approved niraparib (Zejula) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination...
City of Hope Enrolling Patients With Brain Tumors in First-of-Its-Kind Clinical Trial
City of Hope has opened a first-in-human clinical trial for patients with recurrent glioblastoma. The trial is the first to combine City of Hope’s chimeric antigen receptor (CAR) T cells that target the IL13Rα2 antigen common on brain tumor cells in combination with nivolumab and ipilimumab. To...
Pembrolizumab/Lenvatinib in Advanced Endometrial Carcinoma Without Microsatellite Instability–High or Mismatch Repair–Deficient Disease
On September 17, 2019, the combination of pembrolizumab plus lenvatinib was granted accelerated approval for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) and who have disease progression...
Update to FDA Prescribing Information for Romiplostim for Adults With Immune Thrombocytopenia
On October 18, the U.S. Food and Drug Administration (FDA) approved a supplemental biologics license application (sBLA) for romiplostim (Nplate) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia. The updated...
Landmark Studies Show Clear Overall Survival Benefit for CDK4/6 Inhibitors in Advanced Breast Cancer
CDK4/6 inhibitors clearly improve overall survival in advanced breast cancer, as this prized endpoint was robustly demonstrated in two landmark phase III trials reported at the European Society for Medical Oncology (ESMO) Congress 2019. Dennis J. Slamon, MD, PhD, of the University of California,...
Debating the Role of Chemoimmunotherapy in the First-Line Setting of CLL
The advent of new targeted agents for chronic lymphocytic leukemia (CLL) has ushered in a golden age of treatment, leading to longer, more durable periods of disease control. Not all oncologists are convinced, however, that improvements in progression-free survival alone warrant dispensing with...
Three Phase III Trials Suggest Paradigm Shift With PARP Inhibitors in Ovarian Cancer
Ovarian cancer is typically a second-tier newsmaker at the world’s premier oncology conferences, but at the European Society for Medical Oncology (ESMO) Congress 2019, this tumor type generated universal buzz. Impressive findings were presented for three PARP inhibitors in front-line maintenance...
Expert Point of View: Sherene Loi, MD, PhD
Formal discussant Sherene Loi, MD, PhD, Professor of Cancer Therapeutics at the Peter MacCallum Cancer Centre, Melbourne, Australia, characterized the results of KEYNOTE-522 as “exciting.” “This is the first phase III neoadjuvant study in triple-negative breast cancer. Despite breast cancer not...
Phase III Evidence Supports Neoadjuvant Immunotherapy Plus Chemotherapy for Early Triple-Negative Breast Cancer
Immunotherapy has changed the treatment paradigms for melanoma, lung cancer, bladder cancer, and renal cancer. Now, checkpoint inhibitor therapy is making inroads in triple-negative breast cancer—one of the most difficult-to-treat aggressive types of breast cancer. The addition of the checkpoint...
No Survival Benefit With Complete Lymph Node Dissection vs Observation in Sentinel Node–Positive Melanoma
As reported by Leiter et al in the Journal of Clinical Oncology, the final analysis of the German phase III DeCOG-SLT trial have shown no distant metastasis-free survival, recurrence-free survival, or overall survival benefit with complete lymph node dissection vs observation in patients with...
Romiplostim for Patients With Chemotherapy-Induced Thrombocytopenia
In a single-center phase II study reported in the Journal of Clinical Oncology, Soff et al found that treatment with romiplostim was effective in rapidly correcting chemotherapy-induced thrombocytopenia, with maintenance treatment being effective in reducing risk of recurrent chemotherapy-induced...
FLAURA Trial: First-Line Osimertinib Improves Overall Survival in EGFR-Mutated Advanced Lung Cancer
First-line treatment with osimertinib extended overall survival compared with the older tyrosine kinase inhibitors gefitinib and erlotinib in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to late-breaking final overall survival results of the phase III FLAURA...
Ceritinib Active in Treating Brain Metastases in Non–Small Cell Lung Cancer
The ALK inhibitor ceritinib demonstrated efficacy in patients with ALK-positive non–small cell lung cancer (NSCLC) and active brain metastases, according to the results of the ASCEND-7 trial reported at the European Society for Medical Oncology (ESMO) Congress 2019.1 Substantial intracranial...
Anti-GD2 Monoclonal Antibody Plus Induction Chemotherapy in High-Risk Neuroblastoma
A phase II study evaluating whether combining an investigational anti-GD2 monoclonal antibody with induction chemotherapy improved outcomes in children with newly diagnosed high-risk neuroblastoma found that the therapy significantly improved 2-year event-free survival. Furman et al published the...
Studies Suggest Early Salvage Radiotherapy May Be Preferable to Adjuvant Radiotherapy After Prostatectomy
Early salvage radiotherapy appears to be a better choice after radical prostatectomy for men with prostate cancer than adjuvant radiotherapy, according to late-breaking results from the RADICALS-RT trial and the ARTISTIC meta-analysis of three trials that included RADICALS-RT. Observation after...
Community Health Workers May Improve Value of End-of-Life Cancer Care
The results of simple interventions involving community health workers suggest that improvements in value-based cancer care need not come from health-care professionals. According to data presented at the 2019 ASCO Quality Care Symposium,1 reliance upon community health workers trained to assess...
Effect of Tumor Sidedness and Molecular Alterations on Outcomes in Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Morano et al assessed prognostic/predictive role of tumor sidedness and presence of uncommon molecular alterations in anti-EGFR treatment primary resistance in patients with RAS/BRAF wild-type metastatic colorectal cancer. Study Details The...
Multimodal Therapy for High-Risk or Locally Advanced Endometrial Cancer: Is It Any Clearer in 2019?
Endometrial cancer remains the most common gynecologic malignancy affecting women in the United States. There are over 60,000 new cases diagnosed and more than 12,000 deaths annually. Traditional management includes surgical staging, with optimal disease cytoreduction as able, and adjuvant...
Younger, Fit Patients With CLL: Goal Remains Undetectable Minimal Residual Disease and Time-Limited Therapy
As reviewed in this issue of The ASCO Post, Shanafelt and colleagues recently published the interim analysis of E1912, a U.S. Intergroup–led randomized phase III trial comparing ibrutinib/rituximab, followed by ibrutinib to disease progression vs 6 months of fludarabine, cyclophosphamide, and...
Entrectinib for NTRK-Positive Solid Tumors and ROS1-Positive Lung Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On August 15, 2019, the oral TRK, ROS1, and ALK kinase...
Studies Report Prolonged Long-Term Survival With Immunotherapy vs Chemotherapy in Advanced NSCLC
Longer-term follow-up of patients with advanced non–small cell lung cancer (NSCLC) who are treated with immunotherapy have appreciably extended survival at 5 years, suggesting that for some patients, this disease can be managed as a chronic condition. These findings are based on two presentations ...
